Maintenance of remission by tocilizumab mono-therapy after remission obtained by combination with methotrexate in patients with rheumatoid arthritis

Maintenance of remission by tocilizumab mono-therapy after remission obtained by combination with methotrexate in patients with rheumatoid arthritis - Maintenance of remission by tocilizumab mono-therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005590

Enrollment

Registered

2011-05-12

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Cessation of MTX (tocilizumab monotherapy) Continue MTX with tocilizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients in remission for more than 6 months with combination therapy of MTX and tocilizumab

Exclusion criteria

Exclusion criteria: Patients who received treatment listed as below within 6 months; 1) anti-rheumatic drugs except tocilizumab and MTX 2) prednisolone more than 5 mg/day 3) new prescription or dose increase of NSAIDs 4) drugs for osteoporosis such as bisphophonates and SERMs

Design outcomes

Primary

Measure	Time frame
Remission rate at week 52	—

Secondary

Measure	Time frame
Remission rate at week 104 survival rate at week 52 and 104 radiological progression at week 52 and 104 Quality of life at week 52 and 104	—

Countries

Japan

Contacts

Public ContactKoichi Amano

Saitama Medical Center, Saitama Medical Universitity Department of Rheumatology & Clinical Immunology

amanokoi@saitama-med.ac.jp049-228-3859

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026